Neoadjuvant Treatment In Borderline Resectable Pancreatic Adenocarcinoma (Pa): A Single Center Serie.

e15227 Background: Borderline resectable PA may benefit from resection when preceded by neoadjuvant therapy. Methods: We evaluated 22 consecutive patients (pts) with cytology confirmed PA. Borderline resectability was evaluated by multidisciplinary team. Most pts received 6 cycles of gemcitabine 1 g/m2 iv on day 1 and oxaliplatin 100 mg/m2 day 2 (GEMOX) every two weeks. Six pts received the same chemotherapy (CT) schedule plus erlotinib in the context of clinical trial. After re-staging with multidetector computer tomography (MDTC), pts without progressive disease received 5 weeks therapy with 250 mg/m2/d 5-FU infusion and concomitant radiotherapy (50.4 Gy). Pts treated in clinical trial received gemcitabine 40 mg/m2 twice a week and erlotinib 100 mg/d during radiotherapy treatment. After new re-staging with MDTC, pts that did not progress underwent surgical resection. Results: Median follow up for all pts was 12.8 mo. Median age was 63 (range 41-78). After nutritional status evaluation 86.4% had malnutri...